Related Experiment Videos
Thalidomide prolongs experimental autoimmune neuritis in Lewis rats
1Division of Neurology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.
Scandinavian Journal of Immunology
|October 28, 1998
Summary
Thalidomide, used for immune disorders, unexpectedly prolonged experimental autoimmune neuritis in rats. This suggests potential risks, aligning with reported human polyneuropathy and limiting its clinical use.
Area of Science:
- Neuroimmunology
- Immunopharmacology
Background:
- Thalidomide exhibits immunomodulatory and anti-inflammatory properties.
- It is clinically applied in immune-mediated disorders and graft rejection prevention.
- Experimental autoimmune neuritis (EAN) models Guillain-Barré syndrome (GBS).
Purpose of the Study:
- To investigate the therapeutic effect of thalidomide on EAN in Lewis rats.
- To evaluate the immunopathological changes associated with thalidomide treatment in EAN.
Main Methods:
- EAN was induced in Lewis rats using bovine peripheral nerve myelin and complete Freund's adjuvant.
- Thalidomide was administered daily via gavage at 200 mg/kg/day.
- Clinical EAN scores, sciatic nerve histology, and interferon-gamma (IFN-gamma) mRNA expression were assessed.
Main Results:
- Thalidomide administration prolonged the clinical course of EAN.
- Increased inflammatory cell infiltration was observed in the sciatic nerves of treated rats.
- Elevated IFN-gamma mRNA-expressing cells were detected in lymph nodes of thalidomide-treated EAN rats.
Conclusions:
- Thalidomide treatment exacerbated EAN, contrary to its expected anti-inflammatory effects.
- The findings correlate with clinical observations of polyneuropathy in patients treated with thalidomide.
- This study indicates limitations in thalidomide's clinical utility for certain immune-mediated neurological conditions.